Friday, 22 May 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 22 May 2026
News

Who's ready for a June PBS listing?

Posted 22 May 2026 AM

Some big names are contenders for a June PBS listing, with seven drugs sitting in the last stage before reimbursement and another three drugs just a step behind.

Recently joining the wait list is Celltrion Healthcare’s Eylea biosimilar Eydenzelt, specifically intended for subfoveal choroidal neovascularisation due to pathologic myopia plus new indications for AstraZeneca’s Calquence and Amgen’s Blincyto.

To see the whole article, please login

Popular

High-flyer exits corporate world
New CEO announced after 2 years
Drug pulled after less than 3 years
Second drug carves out new niche
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home